The Role of Tacrolimus Ointment in Atopic Dermatitis

  • S. Reitamo

Abstract

Sometimes exciting and important changes occur that comprise a wholly new therapeutic approach, resulting in a sudden and marked improvement within a field of medicine. Throughout the history of medicine it has been these periods of rapid change, the quantum shifts in which one paradigm is superseded by a new and more effective approach, that have marked the course of progress.

Keywords

Corticosteroid Hydrocortisone Histamine Cyclosporin Glaucoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bekersky I, Fitzsimmons W, Tanase A et al. (2001) Nondinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 44: S17–27PubMedCrossRefGoogle Scholar
  2. 2.
    Bode HH (1980) Dwarfism following long-term topical corticosteroid therapy. JAMA 244: 813–814PubMedCrossRefGoogle Scholar
  3. 3.
    Bridgett C, Noren P, Staughton R (1996) Atopic skin disease. A manual for practitioners. Wrightson Biomedical Publishing, PetersfieldGoogle Scholar
  4. 4.
    Caro I, Gordon KB, West DP et al. (2002) Long-term safety of topically applied tacrolimus ointment in adult patients with atopic dermatitis. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 111Google Scholar
  5. 5.
    Charman CR, Morris AD, Williams HC (2000) Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 142: 931–936PubMedCrossRefGoogle Scholar
  6. 6.
    Drake L, Prendergast M, Maher R et al. (2001) The impact of tacrolimus ointment on health related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 44: S65–72PubMedCrossRefGoogle Scholar
  7. 7.
    Dumont FJ (2000) FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 7: 731–748PubMedCrossRefGoogle Scholar
  8. 8.
    Finlay AY (2001) Quality of life in atopic dermatitis. J Am Acad Dermatol 45: S64–66PubMedCrossRefGoogle Scholar
  9. 9.
    Fukaya M (2000) Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 201: 242–245PubMedCrossRefGoogle Scholar
  10. 10.
    Goerz G, Lehmann P (1991) Topical treatment with corticosteroids. In: Ruzicka T, Ring J, Przybilia B (eds) Hand-book of atopic eczema. Springer, Berlin Heidelberg New York Tokyo, pp 375–390CrossRefGoogle Scholar
  11. 11.
    Hanifin JM, Ling MR, Langley R et al. (2001) Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part 1, efficacy. J Am Acad Dermatol 44: S28–38PubMedCrossRefGoogle Scholar
  12. 12.
    Hanifin J, Leung D, Palier A, Rico MJ (2003) Tacrolimus ointment monotherapy is safe and effective for the long-term treatment [more than 3 years] of atopic dermatitis in pediatric patients. 59th Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), Denver, USA, March 7–12, abstractGoogle Scholar
  13. 13.
    Hill CJ, Rosenberg A Jr (1978) Adverse effects from topical steroids. Cutis 21: 624–628PubMedGoogle Scholar
  14. 14.
    Hoare C, Li Wan Po A, Williams H (2000) Systematic review of treatments for atopic eczema. Health Technol Assess 4: 1–189PubMedGoogle Scholar
  15. 15.
    Horn JT, Estridge T (1993) FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils. Clin Immunol Immunopathol 68: 293–300CrossRefGoogle Scholar
  16. 16.
    Hughes J, Rustin M (1997) Corticosteroids. Clin Dermatol 15: 715–721PubMedCrossRefGoogle Scholar
  17. 17.
    Kang S, Lucky AW, Pariser D et al. (2001) Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 44: S58–64PubMedCrossRefGoogle Scholar
  18. 18.
    Kohyama T, Takizawa H Kawasaki S et al. (1999) A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. Mol Cell Biol Res Commun 1: 72–77PubMedCrossRefGoogle Scholar
  19. 19.
    Koo J, Abramovits W, Fivenson D, Horn T, Rico MJ, Jaracz E (2002) The experience of tacrolimus ointment in adult atopic dermatitis patients: the results of two large open-label studies. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 105Google Scholar
  20. 20.
    Leung DYM (1998) Molecular basis of allergic diseases. Mol Genet Metab 63: 157–167PubMedCrossRefGoogle Scholar
  21. 21.
    Leung DYM (2000) Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 105: 860–876PubMedCrossRefGoogle Scholar
  22. 22.
    Leung DYM, Soter NA (2001) Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 44: S1–12PubMedCrossRefGoogle Scholar
  23. 23.
    Leung D, Eichenfield L, Fleischer A et al. (2002) Use of tacrolimus ointment in atopic dermatitis patients with limited disease. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 102Google Scholar
  24. 24.
    Liu J, Albers MW, Wandless TJ et al. (1992) Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 31: 3896–3901PubMedCrossRefGoogle Scholar
  25. 25.
    Lübbe J, Pournaras CC, Saurat JH (2000) Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 201: 249–251PubMedCrossRefGoogle Scholar
  26. 26.
    McLean C, Lobo R, Brazier D (1995) Cataracts, glaucoma, femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 346: 1298PubMedGoogle Scholar
  27. 27.
    Nakagawa H, Etoh T, Ishibashi Y (1994) Tacrolimus ointment for atopic dermatitis. Lancet 344: 883PubMedCrossRefGoogle Scholar
  28. 28.
    Naylor M, Elmets C, Rico JM (2002) Treatment with topical tacrolimus is not associated with an increase in non-melanoma skin cancers. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 18Google Scholar
  29. 29.
    Ngheim P, Pearson G, Langley R (2002) Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 46: 228–241CrossRefGoogle Scholar
  30. 30.
    Palier A, Eichenfield LF, Leung DYM et al. (2001) A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 44: S47–57CrossRefGoogle Scholar
  31. 31.
    Palier AS, Hanifin J, Eichenfield L, Rico MJ, Ayes M (2002) Long-term safety of topically applied tacrolimus ointment in pediatrie patients 2–15 years of age with atopic dermatitis. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 104Google Scholar
  32. 32.
    Panhans-Groß A, Novak N, Kraft S, Bieber T (2001) Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 107: 345–352PubMedCrossRefGoogle Scholar
  33. 33.
    de Paulis A, Cirillo R, Ciccarelli A, Condorelli M, Marone G (1991) FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. J Immunol 146: 2374–2381PubMedGoogle Scholar
  34. 34.
    de Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G (1992) Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 99: 723–728PubMedCrossRefGoogle Scholar
  35. 35.
    Prose NS, Fleischer A, Koo J, Smith ML, Rico MJ, Zheng S (2002) Safety and efficacy of topical tacrolimus ointment in young children age 2–6 years of age with atopic dermatitis. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 103Google Scholar
  36. 36.
    de Prost Y, Bodemer C, Teillac D (1989) Double-blind randomized placebo-controlled trial of local cyclosporine in atopic dermatitis. Arch Dermatol 125: 570PubMedCrossRefGoogle Scholar
  37. 37.
    Protopic (tacrolimus) ointment full prescribing information. Deerfield, Ill: Fujisawa Healthcare Inc., 2002Google Scholar
  38. 38.
    Quielle C, Pommarede R, Saurat JH (1984) Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1: 246–253CrossRefGoogle Scholar
  39. 39.
    Reitamo S, Rissanen J, Remitz A et al. (1998) Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 111: 396–398PubMedCrossRefGoogle Scholar
  40. 40.
    Reitamo S, Wollenberg A, Schöpf E et al. (2000) Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 136: 999–1006CrossRefGoogle Scholar
  41. 41.
    Reitamo S, Rustin M, Ruzicka T et al. (2002) Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 109: 547–555PubMedCrossRefGoogle Scholar
  42. 42.
    Reitamo S, van Leent EJM, Ho V et al. for the European/Canadian Tacrolimus Ointment Study Group (2002) Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate in children with atopic dermatitis. J Allergy Clin Immunol 109: 539–546PubMedCrossRefGoogle Scholar
  43. 43.
    Reitamo S (2003) 0.1% tacrolimus ointment is significantly more efficaceous than a steroid regimen in adults with moderate to severe atopic dermatitis. European Academy of Dermatology and Venerology Spring Symposium, Malta.Google Scholar
  44. 44.
    Remitz A, Kyllönen H, Granlund H, Reitamo S (2001) Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 107: 196–197PubMedCrossRefGoogle Scholar
  45. 45.
    Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C (1982) Cushing’s syndrome after topical application of corticosteroid. Am J Dis Child 136: 247–275Google Scholar
  46. 46.
    Sengoku T, Kishi S, Sakuma S, Ohkubo Y, Goto T (2000) FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 22: 189–201PubMedCrossRefGoogle Scholar
  47. 47.
    Sheehan MP, Rustin MH, Atherton DJ et al. (1992) Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 340: 13–17PubMedCrossRefGoogle Scholar
  48. 48.
    Sheu HM, Chang CH (1991) Alterations in water content of the stratum corneum following long-term topical corticosteroids. J Formos Med Assoc 90: 664–669PubMedGoogle Scholar
  49. 49.
    Soter NA, Fleischer AB Jr, Webster GF et al. (2001) Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 44: S39–46PubMedCrossRefGoogle Scholar
  50. 50.
    Tocci MJ, Matkovich DA, Collier KA et al. (1989) The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143: 718–726PubMedGoogle Scholar
  51. 51.
    Undre NA, Stevenson P, Schafer A (1999) Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 31: 21S–24SPubMedCrossRefGoogle Scholar
  52. 52.
    du Vivier A, Stoughton RB (1975) Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 111: 581–583PubMedCrossRefGoogle Scholar
  53. 53.
    Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T (2001) Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 107: 519–525PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • S. Reitamo

There are no affiliations available

Personalised recommendations